Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
T-PHYL vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
7-9 hours in adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, or with CYP1A2 inhibitors
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4; also undergoes N-demethylation and oxidation.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal (10% unchanged), hepatic metabolism (90%) with metabolites excreted in urine
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
40% bound, primarily to albumin
85-90% bound to albumin.
0.45-0.6 L/kg, approximating total body water; higher in neonates and patients with obesity
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 96-100%; oral sustained-release: 80-90%
Oral: 60-80% (first-pass metabolism reduces bioavailability).
For GFR 10-50 m L/min: administer every 8-12 hours; for GFR <10 m L/min: administer every 12-24 hours.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Starting dose 5 mg/kg/day orally divided every 6 hours; titrate to maximum 10 mg/kg/day.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Start at lowest effective dose (200 mg every 6 hours) and monitor for toxicity due to reduced clearance.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA black box warning is currently required for T-PHYL.
No FDA boxed warning exists for this combination product.
Narrow therapeutic index; monitor serum concentrations. Use with caution in patients with cardiac disorders, hepatic impairment, or peptic ulcer disease. Risk of seizures at high doses. Avoid abrupt discontinuation.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component of the formulation, concomitant use with ephedrine in children.
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
High-protein foods reduce theophylline clearance; high-carbohydrate foods increase clearance. Avoid charcoal-broiled meats and caffeine-containing products (coffee, tea, cola) as they may increase toxicity. Consistency in diet is important to maintain stable serum levels.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: Risk of fetal tachycardia, irritability, and neonatal withdrawal with chronic use.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Excreted into breast milk in low amounts (M/P ratio ~0.3-0.5). Use with caution; monitor infant for irritability or poor feeding.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Increased clearance and volume of distribution in pregnancy may require dose increase by 30-50% to maintain therapeutic levels. Monitor serum concentrations closely.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
T-PHYL (theophylline) requires therapeutic drug monitoring to maintain serum concentrations between 5-15 mcg/m L; levels >20 mcg/m L increase toxicity risk. Cigarette smoking induces its metabolism, requiring dose adjustments. Use with caution in patients with CHF, hepatic impairment, or fever, as clearance decreases. Avoid concurrent use of ciprofloxacin, cimetidine, or macrolides which can elevate levels.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and alcohol; these can alter theophylline levels in your blood.,Report symptoms of toxicity such as nausea, vomiting, insomnia, tremors, or rapid heartbeat.,Do not take over-the-counter medications unless approved by your doctor.,Maintain consistent dietary habits; avoid high-protein or high-carbohydrate diets that affect clearance.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about T-PHYL vs ACCURBRON, answered by our medical review team.
T-PHYL is a Xanthine bronchodilator that works by T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between T-PHYL and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of T-PHYL is: 400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between T-PHYL and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. T-PHYL is classified as Category C. First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: R. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.